Hematologic malignancies

This study tests a condensed version of a chemotherapy regimen (busulfan, melphalan, fludarabine) plus an immune-suppressing drug (ATG) given before a donor stem cell transplant. The goal is to see if this shorter approach causes fewer severe side effects within 30 days after tra…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This early-stage trial tests a new oral drug called KQB198, alone or with another drug (dasatinib), in 13 adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants tak…

This early-stage trial is testing a new drug called GNC-035, a special antibody that targets four different signals on cancer cells. It is being given to 33 adults with blood cancers like lymphoma or leukemia that have come back or not responded to other treatments. The main goal…

This study is creating a large registry of 800 lymphoma patients in Malawi to collect detailed information about the disease. Researchers will perform biopsies and track patients over time to understand how lymphoma affects people in sub-Saharan Africa. The goal is to gather data…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…